Latest Ratios: P/E Ratio -31.6x · EV/EBITDA N/A · ROE -10.9%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.6B | $3.1B | $2.1B | $2.0B | $753M | $833M | $346M | $152M | — | — |
| Enterprise Value | $3.5B | $3.0B | $2.0B | $1.9B | $688M | $747M | $281M | $124M | — | — |
| P/E Ratio → | -31.65 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.27 | 13.99 | 299.88 | 87.52 | 14.79 | 29.83 | 17.71 | — | — | — |
| P/B Ratio | 3.50 | 2.99 | 1.98 | 3.30 | 2.15 | 2.76 | 1.75 | 1.51 | — | — |
| P/FCF | — | — | — | — | — | — | 6.30 | — | — | — |
| P/OCF | — | — | — | — | — | — | 6.24 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.60 | 290.56 | 80.92 | 13.51 | 26.72 | 14.37 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 5.11 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 97.9% | 45.2% | 82.9% | 95.9% | 93.8% | 92.9% | — | — | — |
| Operating Margin | -72.8% | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | -180.9% | — | — | — |
| Net Profit Margin | -52.0% | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | -176.6% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -10.9% | -10.9% | -32.7% | -23.3% | -18.0% | -19.9% | -23.1% | -163.2% | — | — |
| ROA | -10.2% | -10.2% | -31.0% | -21.8% | -15.2% | -14.6% | -16.8% | -40.1% | -60.2% | -67.9% |
| ROIC | -12.4% | -12.4% | -33.6% | -26.8% | -18.8% | -21.7% | -25.7% | -1818.4% | — | — |
| ROCE | -15.0% | -15.0% | -38.5% | -27.5% | -18.1% | -16.9% | -19.3% | -44.9% | -68.6% | -96.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 0.00 | 0.01 | 0.02 | 0.03 | 0.07 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.06 | -0.25 | -0.19 | -0.29 | -0.33 | -0.27 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -1.19 | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($113M) exceeds total debt ($28M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.34 | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Quick Ratio | 11.34 | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Cash Ratio | 10.87 | 10.87 | 14.68 | 19.38 | 11.50 | 5.46 | 7.34 | 14.26 | 16.62 | 5.41 |
| Asset Turnover | — | 0.20 | 0.01 | 0.04 | 0.13 | 0.07 | 0.07 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 0.16 | 0.28 | 1.51 | 14.41 | 35.07 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 15.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $88M | $82M | $58M | $41M | $35M | $25M | $20M | $14M | $14M |
Clinical Milestone Liquidity Dependency
As reported in financial statements, IDYA trades at a P/S multiple of 14.76, a valuation that appears to price in significant future clinical success rather than current earnings, which remains a common characteristic for pre-commercial biotechnology firms operating within the highly speculative precision oncology sector.
The current P/S ratio suggests that investors are assigning a substantial premium to the company's synthetic lethality platform and its strategic partnerships with major pharmaceutical entities. This valuation is highly sensitive to clinical data readouts, and any delay in the MAT2A or PARG programs could lead to significant multiple compression relative to peers like Kura Oncology or Tango Therapeutics.
Based on recent SEC filings, IDYA's ROIC has remained consistently negative, reaching -9.2% in 2026Q1, which underscores the company's current phase of heavy capital deployment into clinical trials that have yet to generate the recurring revenue necessary to achieve a positive return on invested capital.
The persistent negative ROIC is a structural feature of the company's business model, where capital is prioritized for long-term pipeline development rather than near-term efficiency. Investors should monitor whether the company can improve these returns as lead assets transition toward late-stage trials, as current levels indicate significant value destruction if clinical milestones are not met.
According to the provided quarterly data, the company's asset turnover ratio remains extremely low at 0.01 as of 2026Q1, reflecting an asset-light business model that relies on intellectual property and collaboration-driven revenue rather than the high-volume manufacturing typical of traditional industrial or consumer-facing healthcare companies.
The minimal asset turnover is expected given the company's focus on research and development, but it highlights the lack of operational scale currently present in the business. This metric suggests that the company's ability to generate revenue is entirely decoupled from its physical asset base, making traditional efficiency ratios less relevant than clinical progress indicators.
As indicated by the quarterly data, the company's current ratio has compressed significantly from 28.42 in 2024Q1 to 10.74 in 2026Q1, signaling that while the firm maintains a nominal liquidity cushion, the rapid burn rate is steadily eroding the safety margin available for operational contingencies.
While the current ratio appears high compared to broader industrial sectors, it is misleading for a clinical-stage biotech where cash is the primary resource for survival. The rapid decline in this ratio warrants further investigation into the company's cash runway, as the current burn rate may necessitate dilutive financing if milestone payments are delayed.
Based on reported figures, the 82.6% gross margin in 2026Q1 is a misleading indicator of future profitability, as it reflects accounting recognition of collaboration milestones rather than the sustainable, variable-cost-driven margins that would characterize a commercial-stage pharmaceutical company with actual product manufacturing and distribution expenses.
Investors should avoid using this gross margin to project future earning power, as it obscures the high fixed-cost nature of the company's R&D-heavy operations. A more appropriate metric for assessing the company's underlying health would be the cash burn rate relative to the remaining cash runway, rather than traditional margin analysis.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IDYA stock.
IDEAYA Biosciences, Inc.'s current P/E ratio is -31.6x. This places it at the 50th percentile of its historical range.
IDEAYA Biosciences, Inc.'s return on equity (ROE) is -10.9%. The historical average is -41.6%.
Based on historical data, IDEAYA Biosciences, Inc. is trading at a P/E of -31.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
IDEAYA Biosciences, Inc. has 97.9% gross margin and -72.8% operating margin.